Phase I/II – First Administration

443 trials 187 recruiting

Filter these 443 trials by condition, country, sponsor and more.

Open in Search →

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants with… Ended

2023-508697-28-00 Frontotemporal Dementia (FTD) 2024-11-13
Phase I/II Safety and Tolerability Study of striatal administration of AB-1001 in adult subjects with Early Manifest Huntington's Disease (H… Ended

2024-510895-18-00 Huntington's disease 2024-11-07
A Phase 1/2 Study of MK-2870 plus EV plus Pembrolizumab in la/mUC Ended

2023-506387-14-00 Advanced Urothelial Carcinoma 2024-09-24
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women with Recurrent Vulvovaginal Candidiasis: A Randomize… Ended

2023-507527-28-00 Recurrent vulvovaginal candidiasis 2024-09-16
Phase I/II study of ANV600 single agent or in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1) Ended

2023-509633-39-00 Advanced solid tumours 2024-08-06
A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastat… Ended

2023-505655-43-00 Metastatic neuroendocrine prostate cancer 2024-07-29
Allogeneic Tissue Engineering (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers in Advanced Stages, Refractor… Ended

2024-515481-13-00 Corneal trophic ulcers refractory to conventional treat 2024-07-05
Study of Subretinally Injected AAVB-081 in Patients with Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa Ended

2024-518489-29-00 Usher Syndrome Type 1B (USH1B) Retinitis Pigmenotsa 2024-07-01
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours Ended

2023-506228-10-00 Pancreatic Ductal Adenocarcinoma 2024-06-27
Cell-mediated skipping of exon 51 for the genetic correction of dystrophin, based upon a single injection of autologous mesoangioblasts (MAB… Ended

2024-514860-14-00 Duchenne Muscular Dystrophy 2024-06-27
A study evaluating the safety and efficacy of GLPG5101 (19CP02) in subjects with non-Hodgkin lymphoma Ended

2022-502661-23-00 Relapsed/refractory B-cell non-Hodgkin lymphoma 2024-06-11
A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended

2022-501234-37-00 Solid Tumours 2024-05-07
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent gl… Ended

2023-508278-26-01 glioblastoma 2024-04-05
A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intrav… Ended

2023-506737-30-00 Duchenne Muscular Dystrophy 2024-03-08
A Trial of Lu AG13909 in Participants with Congenital Adrenal Hyperplasia Ended

2023-503711-15-00 Congenital adrenal hyperplasia 2024-01-25
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION717 in Patie… Ended

2023-503355-98-00 Prion diseases 2024-01-24
Phase 1/2, Open label & double-blind randomized placebo-controlled study to assess the feasibility of BGC101 (EnEPC) in the treatment of per… Ended

2024-516665-36-00 Peripherial arterial disease (PAD) & Chronic-Limb Threa 2024-01-23
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, TransCon TLR7/8 Agonist, or … Ended

2023-509143-27-00 Locally advanced or metastatic solid tumor malignancies 2023-11-27
A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cell… Ended

2022-500782-27-00 relapsed/refractory Multiple Myeloma 2023-11-14
Therapeutic vaccination: Phase I / II clinical study on patients randomized blinded to the experimental vaccine or placebo regimen. we want … Ended

2024-514581-39-00 HIV Infection 2023-11-08
SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mH… Ended

2023-507672-52-00 PSMA-positive metastatic hormone sensitive prostate can 2023-11-07
A Phase 1/2 Study of BMS-986449 with and without Nivolumab in Participants with Solid Tumors Ended

2023-503484-42-00 Advanced, metastatic, solid malignancy 2023-10-19
Phase I/II study of QEL-001 in A2-mismatch liver transplant patients Ended

2024-516193-30-01 Prevention of liver transplant rejection 2023-10-02
A Phase 1/2a Study of Safety, Pharmacokinetics and Neutralizing Activity of SPK002 as pre-exposure prophylaxis of COVID-19 in healthy volunt… Ended

2023-505279-62-00 Immunocompromised individuals (phase 2a) 2023-07-10